1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;
2. Department of Medicine, University of Toronto, Toronto, ON, Canada;
3. Department of Haematology, University College London Hospital, London, United Kingdom;
4. Department of Oncology, University of Oxford, Oxford, United Kingdom;
5. Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;
6. Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy;
7. Ca’ Granda Ospedale Maggiore Policlinico, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy;
8. Department of Hematology, Ramón y Cajal University Hospital, Madrid, Spain;
9. Department of Internal Medicine, Besançon University Hospital, Besançon, France;
10. Centre for Hemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;
11. Beth Israel Deaconess Medical Center, Boston, MA;
12. Department of Hematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium;
13. Strategic Research Program on CLL, Università Vita Salute and IRCCS Ospedale San Raffaele, Milan, Italy;
14. HCT Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece;
15. Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium;
16. Department of Oncology, Montefiore Medical Center, Bronx, NY;
17. Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and
18. Division of Hematology/Oncology, St. Michael’s Hospital, Toronto, ON, Canada